<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:department>Sch of Psychology</gtr:department><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7561CBD8-8D97-4798-B555-3F2F4AC52FDC"><gtr:id>7561CBD8-8D97-4798-B555-3F2F4AC52FDC</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Norman</gtr:otherNames><gtr:surname>Stephens</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600874"><gtr:id>934E083B-C9B9-4C9D-ADBB-7473AB2ADB84</gtr:id><gtr:title>Involvement of alpha2 subunit-containing GABAA receptors in circuits underlying drug abuse</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600874</gtr:grantReference><gtr:abstractText>Abused drugs such as cocaine and heroin act to facilitate the workings of particular nerve cells that use the chemical messenger, dopamine to communicate with other nerve cells. Dopamine cells have been described by some researchers as forming part of the reward circuitry of the brain. One of the most important kinds of nerve cell with which dopamine cells communicate uses a different chemical messenger, GABA. Drugs such as alcohol and benzodiazepines have their effects on GABA systems. Compared to studies of dopamine, relatively little research has been invested into the function of the GABA system in reward. This project will use mice that have been genetically altered so that particular aspects of GABA signalling are compromised. Specifically, it will investigate the importance of those GABA systems that use GABA receptors that contain the so-called alpha 2 protein, since these kinds of receptor are found in the brain areas involved in learning about the circumstances in which rewards are encountered. Preliminary research suggests that mice genetically engineered so that they cannot make the alpha 2 protein do not show the behavioural adaptations that normal mice display when they repeatedly receive cocaine, which suggests they may not be capable of some kinds of learning about rewards (incentive learning). The project will confirm these preliminary observations, and test the idea in more rigorous, but technically more difficult animal models of drug abuse. If alpha 2-containing GABA receptors can be shown to play an important role in learning about drug rewards, then it may be possible to develop drugs that disable these receptors as a treatment for drug abuse.</gtr:abstractText><gtr:technicalSummary>GABA neurones are intimately involved in brain circuits underlying motivation and reward, and which are the targets for drugs of abuse. The project will make use of mice with either a targeted deletion of the a2 subunit of GABAA receptors, or with a point mutation of the a2 subunit that makes a2-containing GABAA receptors insensitive to benzodiazepines, but sensitive to inverse agonists, to study the roles of a2-containing pathways in drug reward, and in learning about the circumstances in which drugs are delivered. Preliminary evidence indicates that a2 knockout mice fail to sensitise to cocaine, and do not develop a preference for cocaine-paired environments. The planned experiments will replicate these preliminary observations, extend the studies to cocaine self-administration, and will study whether manipulation of a2-containing GABAA receptors influences either cue-induced, or drug-induced relapse to cocaine seeking following extinction. Intracranial administration of drugs acting at the benzodiazepine site of a2-containing GABA receptors will be used to identify brain regions involved in these effects.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>329804</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>provision of genetically manipulated mice</gtr:description><gtr:id>9A6C6F5D-3DF8-4243-B4F9-93F3012431CC</gtr:id><gtr:impact>PMD 19501766 PMD 18313124 PMD 18358520 PMD 16706856</gtr:impact><gtr:outcomeId>E2E10E3F0F5-1</gtr:outcomeId><gtr:partnerContribution>Partner provided 2 strains of genetically manipulated mice</gtr:partnerContribution><gtr:piContribution>Behavioural and neurobiological characterisation of genetically manipulated mice</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Addiction Cluster Grant</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>B8FE93EA-B1AC-42D9-88B4-2E4F20AD2795</gtr:id><gtr:outcomeId>BCCFDBC7C090</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>34260</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Contribution to BBSRC Case studentship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>99D270D3-593A-4C30-A02F-37DF3F7ED7C4</gtr:id><gtr:outcomeId>JWuJgHzHCy90</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F4E753EF-2E53-422B-82D9-C8B61DC66AA2</gtr:id><gtr:outcomeId>bJjxEqN9XJP0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>104385</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Addiction Call Stage 1</gtr:description><gtr:end>2010-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0872A296-BA6D-431F-A28A-2FF62FFEECD9</gtr:id><gtr:outcomeId>B4E995F4B630</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70820</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>bbsrc CASE studentship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>397FE317-3BC2-47CD-92E9-65F75D51BE9A</gtr:id><gtr:outcomeId>aQ1YMW6dg770</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>847FC1AA-E987-4FC5-919B-970A53EA443D</gtr:id><gtr:title>Single Nucleotide Polymorphism Associated with Altered Brain Responses (but not Performance) during Measures of Impulsivity and Reward Sensitivity in Human Adolescents.</gtr:title><gtr:parentPublicationTitle>Frontiers in behavioral neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb946697bc0f9579fb05719e815034d2"><gtr:id>bb946697bc0f9579fb05719e815034d2</gtr:id><gtr:otherNames>Duka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1662-5153</gtr:issn><gtr:outcomeId>58c6abe61bd456.57812294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B6A68FD-58BB-4FC2-832C-F7E3AC6F15DF</gtr:id><gtr:title>Deletion of the gabra2 gene results in hypersensitivity to the acute effects of ethanol but does not alter ethanol self administration.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d86a37a8e51f63a523c035fb39e6196"><gtr:id>0d86a37a8e51f63a523c035fb39e6196</gtr:id><gtr:otherNames>Dixon CI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_55f9849840930a78</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C25ADCFB-D492-4CAA-B769-0A53D6015C80</gtr:id><gtr:title>Mutations in the Gabrb1 gene promote alcohol consumption through increased tonic inhibition.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24c89a46bc4fc9d556fe9b4dc2be9826"><gtr:id>24c89a46bc4fc9d556fe9b4dc2be9826</gtr:id><gtr:otherNames>Anstee QM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_540e14de14d1361bd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18C75F8B-332F-42A9-AD81-175E276817B9</gtr:id><gtr:title>Alpha1- and alpha2-containing GABAA receptor modulation is not necessary for benzodiazepine-induced hyperphagia.</gtr:title><gtr:parentPublicationTitle>Appetite</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c821a04bf62033a32b582e5d4bbb54e"><gtr:id>3c821a04bf62033a32b582e5d4bbb54e</gtr:id><gtr:otherNames>Morris HV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0195-6663</gtr:issn><gtr:outcomeId>3233DB6F502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2052EF8D-32C4-48B9-9EC1-970D544ED1CA</gtr:id><gtr:title>Modeling appetitive Pavlovian-instrumental interactions in mice.</gtr:title><gtr:parentPublicationTitle>Current protocols in neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f0b2f021c0abc029154235df8907017"><gtr:id>6f0b2f021c0abc029154235df8907017</gtr:id><gtr:otherNames>O'Connor EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1934-8576</gtr:issn><gtr:outcomeId>gotmsCjZw6f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A954E69F-5CFC-472D-90C9-B294B7CA2E37</gtr:id><gtr:title>Deletion of the GABAA a2-subunit does not alter self administration of cocaine or reinstatement of cocaine seeking.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d86a37a8e51f63a523c035fb39e6196"><gtr:id>0d86a37a8e51f63a523c035fb39e6196</gtr:id><gtr:otherNames>Dixon CI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>pm_540e14de14d1da6c9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F4296D5-BF00-4242-A69E-3513F54418FB</gtr:id><gtr:title>Both alpha2 and alpha3 GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in the conditioned emotional response paradigm.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c821a04bf62033a32b582e5d4bbb54e"><gtr:id>3c821a04bf62033a32b582e5d4bbb54e</gtr:id><gtr:otherNames>Morris HV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>84970365489</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D4EBA74-8E19-4DD6-9421-E67279A1D7E9</gtr:id><gtr:title>Targeted deletion of the GABRA2 gene encoding alpha2-subunits of GABA(A) receptors facilitates performance of a conditioned emotional response, and abolishes anxiolytic effects of benzodiazepines and barbiturates.</gtr:title><gtr:parentPublicationTitle>Pharmacology, biochemistry, and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d86a37a8e51f63a523c035fb39e6196"><gtr:id>0d86a37a8e51f63a523c035fb39e6196</gtr:id><gtr:otherNames>Dixon CI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0091-3057</gtr:issn><gtr:outcomeId>CEE6AE981DE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B8A8C8C-2102-4653-9451-85ACE685C781</gtr:id><gtr:title>Cocaine effects on mouse incentive-learning and human addiction are linked to alpha2 subunit-containing GABAA receptors.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d86a37a8e51f63a523c035fb39e6196"><gtr:id>0d86a37a8e51f63a523c035fb39e6196</gtr:id><gtr:otherNames>Dixon CI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>24CA931B62B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73F362D4-2A5E-4DC6-ACDA-1713918696D9</gtr:id><gtr:title>Alpha2-containing GABA(A) receptors are involved in mediating stimulant effects of cocaine.</gtr:title><gtr:parentPublicationTitle>Pharmacology, biochemistry, and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c821a04bf62033a32b582e5d4bbb54e"><gtr:id>3c821a04bf62033a32b582e5d4bbb54e</gtr:id><gtr:otherNames>Morris HV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0091-3057</gtr:issn><gtr:outcomeId>4CF47097F60</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600874</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>